Skip to main content

The Radioactive Drug Research Committee (RDRC)

By Troy Zhou, PhD, DABR, DABSNM
October 21, 2025 • 16 min read
#Nuclear Medicine #Radiation Safety #Risk Management #Patient Safety #ALARA

The Radioactive Drug Research Committee (RDRC) is the FDA-approved pathway, under 21 CFR 361.1, that lets institutions conduct basic research with radioactive drugs in humans without filing an Investigational New Drug (IND) application — as long as the drug is used purely as a tracer, the mass produces no pharmacologic effect, and the radiation dose stays within defined limits. For academic medical centers, cyclotron facilities, and imaging research programs, the RDRC is the quiet regulatory engine behind a large share of exploratory PET and SPECT research. It is also frequently misunderstood: an RDRC does not replace the IRB, and it does not grant authority to possess radioactive material. 12

This guide explains what the RDRC pathway covers, the pharmacologic and radiation dose limits, committee composition, subject and reporting requirements, and how RDRC approval fits alongside the Institutional Review Board (IRB) and the facility's radioactive-material license. DRPS supports research programs through its radioactive material license support and radiation safety officer services across Florida, Maryland, Virginia, Washington DC, California, Nevada, Pennsylvania, New York, New Jersey, and Delaware.

Introduction

When a new radiopharmaceutical is developed to diagnose or treat disease, its clinical investigation proceeds under an IND with full FDA oversight. But a great deal of valuable research does not aim to prove a drug safe or effective for patients — it uses a radioactive drug as a tracer to answer a scientific question about how the body works: a receptor's density, a metabolic rate, an organ's kinetics. In 1975 the FDA recognized that this basic research, conducted at tracer levels, poses little risk and does not fit the IND framework. The result is 21 CFR 361.1, which declares certain radioactive drugs "generally recognized as safe and effective" for basic research when used under the supervision of an FDA-approved Radioactive Drug Research Committee. 13

The RDRC is therefore a delegation of authority: rather than the FDA reviewing each basic-research protocol individually, a qualified institutional committee applies fixed criteria — pharmacologic mass, radiation dose, scientific merit, and subject protection — and reports to the FDA. Understanding those criteria is essential for any physicist, radiation safety officer (RSO), or investigator who supports research imaging, because the boundaries are precise and the consequences of crossing them (an unapproved clinical trial without an IND) are serious. 23

Topic Explanation

What the RDRC pathway covers — and what it does not

The RDRC pathway is limited to basic research intended to advance scientific knowledge. Under 21 CFR 361.1, the research must be for obtaining basic information regarding metabolism (including kinetics, distribution, and localization) of a radioactively labeled drug, or regarding human physiology, pathophysiology, or biochemistry — not to carry out a clinical trial or to determine the drug's safety and effectiveness for a diagnostic or therapeutic use. 1

Three bright lines define eligibility:

  • No intended clinical benefit. The radioactive drug is a research tool, not diagnosis or therapy for the subject.
  • No pharmacologic effect. The mass administered must be low enough to produce no clinically detectable pharmacologic effect in the subject — the tracer principle.
  • Within dose limits. The radiation dose to research subjects must not exceed the limits in the regulation.

If any of these fails — for example, a study designed to establish that a tracer accurately diagnoses a condition, or one using a pharmacologically active mass — the work belongs under an IND, not the RDRC. 13 For related background on who may direct clinical radiopharmaceutical use, see our article on authorized user and medical physicist training and experience.

The role of the committee

The RDRC is an institutional committee approved by the FDA. For each proposed study it must find that the pharmacologic dose is within limits, the radiation dose is within limits, the radiation exposure is justified by the quality of the study and its scientific value, the investigator is qualified and appropriately licensed, the radioactive drug is of suitable quality, and the study has been approved by an appropriate IRB. The committee documents these findings and, critically, reports its activity to the FDA. 12

Establishing a committee is itself an FDA action: an institution applies for RDRC approval, demonstrates that its membership meets the composition requirements, and commits to the recordkeeping and reporting obligations before it may approve any study. Approval is not permanent by default — the committee's standing depends on continued compliance, timely annual reports, and prompt notification of changes such as membership turnover. The annual report is the FDA's primary window into RDRC activity: it summarizes each active study, the number of subjects and their doses, and any adverse reactions observed. A committee that lets its reporting lapse, drifts below the required expertise, or approves work outside the basic-research boundary risks losing the delegated authority that makes the whole pathway function. 123

Key Technical Principles

Radiation dose limits for research subjects

The heart of 21 CFR 361.1 is a table of dose limits, expressed in the traditional unit of rem (1 rem = 0.01 sievert). They distinguish the most radiosensitive tissues from other organs, and single-administration from annual exposure: 1

Target tissue Single dose Annual and total dose commitment
Whole body, active blood-forming organs, lens of eye, gonads 3 rem (0.03 Sv) 5 rem (0.05 Sv)
Other organs 5 rem (0.05 Sv) 15 rem (0.15 Sv)
Research subjects under 18 years of age ≤ 10% of the above ≤ 10% of the above

The "annual and total dose commitment" reflects that some radiopharmaceuticals deliver dose over an extended period as they decay and clear; the committed dose must be counted. For minors, every limit is reduced to one-tenth of the adult value, a deliberately conservative margin for developing tissues. 1 These research-subject limits are distinct from — and generally far below — the occupational dose limits that govern staff under NRC 10 CFR Part 20.

Worked example: a typical PET tracer study

Consider an adult FDG research scan. The effective dose coefficient for F-18 FDG is approximately 0.019 mSv/MBq (ICRP Publication 128). For an administered activity of 370 MBq (10 mCi):

That whole-body-equivalent magnitude of about 0.7 rem sits comfortably below the 3 rem single-dose and 5 rem annual limits for the whole body, leaving room — under the annual cap — for repeat scans or an accompanying CT within a research protocol. 19 Two cautions apply. First, 21 CFR 361.1 predates the modern effective-dose formalism and is written in terms of specific tissues, so a rigorous RDRC dosimetry evaluation must confirm the organ doses (for the critical organ, which for FDG is typically the bladder wall), not merely an effective-dose estimate. Second, any accompanying imaging radiation — such as a co-registered CT for attenuation correction — contributes to the subject's research dose and must be included in the assessment. 18

Pharmacologic mass and the tracer principle

The requirement of "no clinically detectable pharmacologic effect" is what keeps the research at true tracer levels. In practice this is why radiochemists work to achieve high specific activity: the administered mass of the labeled compound is tiny — often micrograms or less — so that the moles delivered are far below any pharmacologically active threshold. The RDRC evaluates the total mass, including any unlabeled carrier, against known pharmacology. When the mass approaches a level with measurable physiologic effect, the RDRC pathway no longer applies. 13

Clinical Impact

The RDRC pathway is what makes exploratory molecular-imaging research practical at the institutional level. By delegating routine basic-research oversight to a qualified local committee, it lets investigators test new tracers' kinetics and biodistribution, validate quantification methods, and pursue physiology studies without the time and cost of a full IND — while still enforcing dose limits, subject protections, and FDA reporting. For a cyclotron-equipped academic center producing novel F-18 and Ga-68 compounds, the RDRC is often the day-to-day gateway to first-in-human tracer characterization. 23

The pathway also shapes program structure. Because RDRC approval, IRB approval, and radioactive-material licensing are three separate authorizations, a research imaging program needs coordinated governance: the RDRC handles the radioactive-drug-specific findings; the IRB handles human-subject protection and consent; and the RSO and authorized users handle possession, safe use, and disposal under the materials license. A gap in any one of them stops the study — or, worse, exposes the institution to an enforcement finding. Well-run programs align these bodies so that a protocol clears all three in parallel, with the dosimetry and pharmacologic-mass assessments shared across the RDRC and the radiation safety committee. See our overviews of the radiation safety committee and the radiation safety officer role.

Practical Optimization Tips

Get the classification right first

  • Ask the intent question before anything else. Is the study basic research (metabolism, physiology, biochemistry) with no clinical benefit to the subject? If it aims to prove diagnostic or therapeutic performance, it needs an IND, not the RDRC. 13
  • Confirm the mass is non-pharmacologic with a documented specific-activity and total-mass assessment, including carrier.
  • Do the dosimetry against organ limits, not just an effective-dose estimate, and include any co-acquired CT or transmission dose. 1

Build a defensible committee and file

  • Seat the required expertise: a nuclear medicine physician, a radiopharmaceutical formulation expert, and a radiation-safety/dosimetry expert, with at least five members total. 12
  • Document each required finding — pharmacologic dose, radiation dose, scientific merit, investigator qualification, drug quality, and IRB approval — in the meeting record.
  • Track the 30-subject threshold. Plan a special summary to FDA before a study exceeds 30 subjects. 1
  • Calendar the annual FDA report and the immediate reporting of any adverse reaction. 12

Keep the three authorizations aligned

  • Map RDRC, IRB, and license conditions for each protocol so no study proceeds missing one.
  • Coordinate with the RSO so administered activities, waste, and surveys stay within the materials license and ALARA program.

Regulatory Considerations

The RDRC sits at the intersection of FDA drug regulation and NRC/Agreement State materials regulation, and it satisfies neither on its own. The governing frameworks: 125

  • 21 CFR 361.1 — the FDA regulation that defines the RDRC, its findings, the pharmacologic and radiation dose limits, committee composition, the 30-subject threshold, and the annual reporting duty. 1
  • FDA RDRC Program guidance (2010) — The Radioactive Drug Research Committee: Human Research Without an Investigational New Drug Application, which explains how the committee operates and how to distinguish RDRC-eligible research from studies needing an IND. 3
  • NRC Policy and Guidance Directive FC 86-1, Rev 1 — clarifies the relationship between RDRC approval and the NRC materials-licensing framework; RDRC approval does not authorize possession of byproduct material. 5
  • 10 CFR Part 20 and 10 CFR Part 35 (or the Agreement State equivalent) — govern possession, medical use, occupational and public dose limits, and disposal for the radioactive material the study uses. 67
  • ICRP guidance on biomedical research (Publication 62, with dose coefficients from Publication 128) — provides the radiation-protection framework and dosimetry data used to justify research exposures. 89

Because DRPS serves both direct-NRC jurisdictions (Washington DC and Delaware for byproduct material) and NRC Agreement States (Florida, Maryland, Virginia, California, Nevada, Pennsylvania, New York, and New Jersey), a research program must confirm which authority issues its materials license and how its rules interact with the federal RDRC pathway. The RDRC finding is federal (FDA); the possession authority is NRC or state. DRPS coordinates the radiation-safety side of research imaging with radioactive material license support, RSO program guidance, and PET/CT and nuclear medicine physics support. 567

Frequently Asked Questions (FAQs)

What is a Radioactive Drug Research Committee (RDRC)?

An RDRC is an FDA-approved institutional committee that authorizes certain basic research uses of radioactive drugs in humans without an Investigational New Drug (IND) application, under 21 CFR 361.1. It reviews the pharmacologic mass dose, the radiation dose to research subjects, the scientific merit, investigator qualifications, and subject protections, and it reports its activity to the FDA annually.

When can research use an RDRC instead of an IND?

The RDRC pathway applies only to basic research intended to advance scientific knowledge — studying metabolism, physiology, biochemistry, or pathophysiology — where the radioactive drug is used as a tracer with no intended therapeutic or diagnostic benefit to the subject and no clinically detectable pharmacologic effect. Research meant to establish the safety or effectiveness of the drug for a clinical indication requires an IND, not an RDRC.

What are the RDRC radiation dose limits?

For adult subjects, 21 CFR 361.1 limits the dose to the whole body, active blood-forming organs, lens of the eye, and gonads to 3 rem (0.03 Sv) per single dose and 5 rem (0.05 Sv) per year; for all other organs the limits are 5 rem per single dose and 15 rem (0.15 Sv) per year. For research subjects under 18 years of age, the dose must not exceed 10 percent of these adult limits.

Who must serve on an RDRC?

An RDRC must have at least five members and must include a physician recognized as a specialist in nuclear medicine, a person qualified by training and experience to formulate radioactive drugs (radiopharmaceutical chemistry), and a person with special competence in radiation safety and radiation dosimetry. The remaining members are qualified in disciplines pertinent to nuclear medicine. The FDA approves each committee.

How many research subjects can an RDRC study enroll?

An RDRC-approved study ordinarily involves no more than 30 research subjects. If a study proposes to involve more than 30 subjects, a special summary must be submitted to the FDA for review before those additional subjects are exposed. The committee also files an annual report to the FDA summarizing its approved studies and any adverse reactions.

Does an RDRC replace IRB review or a radioactive-material license?

No. RDRC approval is in addition to, not a substitute for, Institutional Review Board approval and informed consent. It also does not grant authority to possess or use radioactive material — that comes from the facility's NRC or Agreement State radioactive-material license under 10 CFR Parts 20 and 35 or the equivalent state rules. All three must be in place.

What is the difference between the RDRC pathway and microdosing under an exploratory IND?

Both study drugs at very low, non-pharmacologic mass levels, but the RDRC pathway is a distinct FDA framework specific to radioactive drugs used as tracers in basic research, governed by 21 CFR 361.1 and its radiation dose limits. Exploratory IND microdosing is a separate IND-based route with its own definitions and is used when the RDRC criteria — basic research intent, dose limits, and no pharmacologic effect — are not met.

Key Takeaways

  • The RDRC is 21 CFR 361.1's pathway for basic research with radioactive drugs used as tracers, without an IND. 1
  • Three bright lines gate eligibility: basic-research intent, no clinically detectable pharmacologic effect, and radiation dose within limits. 13
  • Adult dose limits are 3 rem/5 rem (single/annual) for whole body, blood-forming organs, lens, and gonads, and 5 rem/15 rem for other organs; minors get 10% of these. 1
  • The committee needs ≥5 members, including a nuclear medicine physician, a radiopharmaceutical-formulation expert, and a radiation-safety/dosimetry expert. 12
  • Studies over 30 subjects trigger a special FDA summary, and the RDRC files an annual FDA report. 1
  • RDRC, IRB, and the materials license are three separate authorizations — RDRC approval never substitutes for the others. 156

Conclusion

The Radioactive Drug Research Committee is a small piece of regulation with an outsized role in molecular-imaging research: it turns the tracer principle into a workable, self-governing pathway that lets institutions explore new radiopharmaceuticals' biology without a full IND, while still protecting subjects with hard dose limits and FDA reporting. Its power depends on discipline — classifying research correctly, seating the right expertise, doing the dosimetry against organ limits, and keeping RDRC, IRB, and materials-license authorizations aligned. Treated that way, the RDRC is not red tape; it is the mechanism that makes safe, defensible, and productive radioactive-drug research possible.

How DRPS Can Help

Diagnostic Radiation Physics Services helps research imaging programs build the radiation-safety foundation that RDRC work depends on: subject and staff dosimetry evaluations, radioactive-material license support and amendments, RSO program and radiation safety committee guidance, and coordination with authorized users — delivered through radioactive material license support, radiation safety officer, and medical physics consulting services. Our board-certified medical physicists support facilities across our service locations, including Florida, Maryland, Virginia, Washington DC, California, Nevada, New York, Pennsylvania, New Jersey, and Delaware.

A strong research imaging program is not just about committee approvals. It is about a documented chain — intent, mass, dose, and license — that stands up to FDA and inspection review.

Related Resources

References

  1. U.S. Food and Drug Administration. 21 CFR 361.1: Radioactive drugs for certain research uses. Code of Federal Regulations. ecfr.gov
  2. U.S. Food and Drug Administration. Radioactive Drug Research Committee (RDRC) Program. fda.gov
  3. U.S. Food and Drug Administration. Guidance for Industry and Researchers — The Radioactive Drug Research Committee: Human Research Without an Investigational New Drug Application. August 2010. fda.gov
  4. U.S. Food and Drug Administration. What Are the Qualifications and Requirements for RDRC Membership? fda.gov
  5. U.S. Nuclear Regulatory Commission. Policy and Guidance Directive FC 86-1, Revision 1: Radioactive Drug Research Committees. nrc.gov
  6. U.S. Nuclear Regulatory Commission. 10 CFR Part 20: Standards for Protection Against Radiation. nrc.gov
  7. U.S. Nuclear Regulatory Commission. 10 CFR Part 35: Medical Use of Byproduct Material. nrc.gov
  8. International Commission on Radiological Protection. ICRP Publication 62: Radiological Protection in Biomedical Research. Annals of the ICRP. 1991;22(3). icrp.org
  9. International Commission on Radiological Protection. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals — A Compendium of Current Information Related to Frequently Used Substances. Annals of the ICRP. 2015;44(2S). icrp.org
  10. U.S. Food and Drug Administration. Guidance for Industry, Investigators, and Reviewers — Exploratory IND Studies. 2006. fda.gov